top of page
The Professional Network for Healthcare Experts
European Commission approves Icotyde for moderate-to-severe plaque psoriasis
The European Commission has authorised Icotyde for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
nuaxia
Sep 231 min read
EMA recommends Icotyde for EU authorisation in moderate-to-severe plaque psoriasis
If authorised, Icotyde would become the first oral treatment targeting the interleukin-23 receptor available to eligible adults and adolescents in the EU.
nuaxia
Jul 272 min read
bottom of page